The short version
Tirzepatide can reduce the effectiveness of oral contraceptives. Delayed gastric emptying changes how much of a pill is absorbed, and the effect is largest when the level of the drug is changing rather than settled. The product information addresses this directly and advises non-oral contraception, or an added barrier method, around the times when it matters.
Semaglutide and liraglutide do not carry the same warning. Their effect on gastric emptying is real but the pharmacokinetic studies did not find a clinically meaningful reduction in oral contraceptive exposure, so the guidance for them is different.
When the warning applies
This is the part that gets lost, because people hear the warning once and either ignore it forever or treat it as permanent. Neither is what the label describes. It attaches to two moments:
When you start
The first four weeks of treatment, when your body is meeting the drug for the first time and the level is climbing from nothing toward its first plateau.
After every dose increase
Four weeks following each step up the ladder. Every increase restarts the same climb, so a person who titrates through several doses passes through this window several times.
The recommended handling is either to switch to a non-oral method, or to add a barrier method for those four weeks. Which of those is right depends on your circumstances and is a decision for the person who prescribes it.
Note what follows from the four-week rule. Someone climbing from the starting dose to a maintenance dose over several months is not in one long window; they are in a series of them, and the gaps between are the settled stretches. Your dose schedule and your window are the same calendar, which is exactly why it is worth having that calendar written down.
Why gastric emptying does this
An oral contraceptive has to dissolve and be absorbed to work, and absorption happens past the stomach. Slowing the rate at which the stomach empties changes both the timing and, at the margins, the amount that gets through.
The effect concentrates around dose changes for the same reason side effects do. The slowing of gastric emptying is at its most pronounced when the level is rising and the body has not adapted to it, and it attenuates as the level settles. That is why the label attaches a four-week window to each change rather than a blanket warning for the whole course of treatment.
The same mechanism is behind the nausea and constipation that peak after an increase, and behind why the days right after an injection feel different from the days before the next one. It is one physiological fact with several practical consequences.
Pregnancy, and stopping before trying
Separate from the contraception question, these medications are not for use in pregnancy. The product information advises discontinuing before a planned pregnancy, with the recommended interval reflecting how long the drug takes to clear.
| Medication | Half-life | Practically gone after |
|---|---|---|
| Tirzepatide | About 5 days | About 25 days |
| Semaglutide, weekly | About 7 days | About 5 weeks |
| Liraglutide | About 13 hours | About 3 days |
Clearance arithmetic only. The interval your prescriber advises before conception is a clinical recommendation and is generally longer than clearance alone, so take it from them and not from this table.
Two things follow that people find counterintuitive. Weight loss can restore ovulation in someone who was not ovulating reliably before, which means fertility can return before anyone plans for it. And the clearance interval is not the same as the advised interval; the label allows for a margin. The half-life page for semaglutide and the one for tirzepatide explain where the clearance numbers come from.
What to write down
The whole difficulty here is a calendar problem. The window is defined by a date you will not remember four months from now.
- The date of every dose increase. This is the one that matters, because the four weeks run from it. A guessed date is not good enough for this purpose.
- Which dose you moved to. Useful for the conversation at your next appointment and for reconstructing the sequence later.
- When each window closes. Four weeks after each increase. Knowing it is over is as useful as knowing it started.
- What you agreed with your prescriber. Whether you switched methods or added one, so that six months later there is a record rather than a recollection.
Penwise records dose changes as dated events rather than as a single current setting, so the date an increase happened is still there months afterwards. That is the same reason the missed dose and injection day pages keep coming back to dates: on these medications, most practical questions turn out to be questions about a calendar.
Every dose change, with the date attached
Dose increases recorded as dated events, so a four-week window is something you can see. Free core tracker, no account needed.
Common questions
Does Mounjaro affect birth control?
Does Ozempic or Wegovy affect the pill?
How long does the contraception warning last on tirzepatide?
Does the warning apply again after every dose increase?
How long before pregnancy should I stop a GLP-1?
Can these medications make me more fertile?
Sources
Every factual claim on this page traces to the product information a regulator publishes, or to a published trial. Links open on the site of whoever issued the document.
- Mounjaro: EPAR product information European Medicines Agency
- Wegovy: EPAR product information European Medicines Agency
- Ozempic: EPAR product information European Medicines Agency
Penwise is a tracking and education tool, not a medical device. Nothing on this page is medical advice, a diagnosis or a recommendation to start, stop or change a dose. Dosing decisions belong to you and your clinician. Ozempic, Wegovy, Rybelsus, Saxenda and Victoza are trademarks of Novo Nordisk; Mounjaro, Zepbound and Trulicity are trademarks of Eli Lilly. Penwise is not affiliated with, endorsed by or connected to either company.